Insight Medbotics CEO and Board of Directors member Fazila Seker was among the healthcare leaders speaking at TechTO’s Health Toronto event on September 10, 2025.
Her talk, “The Craft of Building Traction for your MedTech Startup: Untold Stories from the Road Less Traveled,” helped builders in the audience to understand their target customers, how industry alliances work, and gain the insight needed to create traction in a challenging technology market.
“What does it take to create products that impact people’s lives?” she asked the audience while describing her past success growing MOLLI Surgical, a medical device company in the breast cancer surgery space (Stryker acquired the company in 2024). “What I’ve learned from my experiences and studying the successes of others is that a key first step is falling in love with your customer, not your tech.”
Seker stressed the importance of simple, consistent messaging, a coherent customer experience and building a team who share the company’s vision and values. That’s the kind of foundation that sets new Medtech ventures up to win over the people who will champion their technology: clinicians and patients who must see a clear benefit to change.
The event, organized in tandem with OneEleven, brought together leaders, founders, investors, engineers, and product managers who are transforming healthcare through technology.
Here’s her speaker description from the TechTO teaser:
Fazila Seker, CEO of Insight Medbotics, is revolutionizing prostate cancer care with MRI-compatible robotics. As a second-time founder with a successful exit in the breast cancer space, her company’s technology provides greater precision for needle procedures in soft tissues, a problem affecting millions. The inspiration for the company’s direction came from extensive market research and direct conversations with physicians who rely on MRI information but lack the tools to perform procedures inside the machine. Now, with a FDA 510(k) clearance (the only company to achieve this for use of a robot with an MRI) and a growing list of interested hospitals and strategic partners, the market’s strong reception is a testament to the team’s rigorous upfront discovery and how new innovations continue to propel Insight Medbotics forward in the space.
